Compare · MRK vs TALS
MRK vs TALS
Side-by-side comparison of Merck & Company Inc. (MRK) and Talaris Therapeutics Inc. (TALS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and TALS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $364.26B.
- MRK has hit the wire 18 times in the past 4 weeks while TALS has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 3 for TALS).
- Company
- Merck & Company Inc.
- Talaris Therapeutics Inc.
- Price
- -
- -
- Market cap
- $364.26B
- -
- 1M return
- +1.70%
- -
- 1Y return
- +59.16%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 3
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Talaris Therapeutics Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Latest MRK
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Latest TALS
- SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)
- SEC Form SC 13G filed by Talaris Therapeutics Inc.
- SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)
- SEC Form SC 13G filed by Talaris Therapeutics Inc.
- SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)
- Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)
- Talaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 424B5 filed by Talaris Therapeutics Inc.